drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19 for treatment of relapsed or refractory non-Hodgkin lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting CD19 on B cells. Antigen binding activates CAR signaling (CD3ΞΆ plus costimulatory domains such as CD28 or 4-1BB), driving T-cell proliferation, cytokine release, and perforin/granzyme-mediated cytolysis of CD19-positive malignant B cells.
drug_name
CD19-directed CAR-T cells
nct_id_drug_ref
NCT06522932